Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

Executive Summary

• Satellos Bioscience announced the first participant has been dosed in BASECAMP, a Phase 2 pediatric study of SAT‑3247 for Duchenne muscular dystrophy (DMD).
• The trial will enroll 51 ambulatory children aged 7‑9 across up to 25 sites globally and will assess safety, tolerability, muscle force, quality, function and regeneration.
• BASECAMP is positioned as a potential pivotal trial that could accelerate development of SAT‑3247 as a disease‑modifying therapy for DMD.

Key Details

• Study Design: Randomized, double‑blind, placebo‑controlled, three‑month proof‑of‑concept Phase 2 trial (BASECAMP).
• Target Population: 51 ambulatory children with DMD, ages 7, 8 or 9 years.
• Primary Endpoints: Safety, tolerability, and effect on muscle force.
• Secondary Endpoints: Muscle quality, functional performance, and regeneration metrics.
• Geographic Reach: Up to 25 clinical sites in the United States, Europe, United Kingdom, Australia, Canada, and Serbia.
• First Dose Administered: Date of first participant dosing disclosed (study now actively enrolling).
• CEO Quote (Frank Gleeson): Emphasized BASECAMP as a “significant step” and its potential to accelerate SAT‑3247 development toward pivotal status.
• CMO Quote (Wildon Farwell, M.D.): Highlighted the unmet need in DMD and the trial’s focus on a disease stage where muscle decline accelerates.

Notable Quotes

“Designed as a potential pivotal trial, BASECAMP marks a significant step for Satellos in evaluating the therapeutic potential of SAT‑3247 in children living with Duchenne,” – Frank Gleeson, Co‑founder & CEO.

“Treatment options remain limited for this devastating disease, and this study will evaluate a novel approach to potentially increase muscle regeneration and thereby improve function among children with Duchenne,” – Wildon Farwell, M.D., Chief Medical Officer.